- Home
- QSI vs MOLN Comparison
QSI vs MOLN Comparison
Compare QSI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QSI | MOLN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 170.5M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QSI | MOLN |
|---|---|---|
| Price | $1.43 | $3.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.30 | ★ $10.36 |
| AVG Volume (30 Days) | ★ 2.1M | 1.5K |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,436,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $406.32 | $450.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $3.53 |
| 52 Week High | $3.10 | $5.36 |
Technical Indicators
Market Signals| Indicator | QSI | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 78.88 | 44.22 |
| Support Level | $1.16 | $3.79 |
| Resistance Level | $1.33 | $4.39 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 90.82 | 16.49 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.